Edoardo Nicolò Aiello, Alfonsina D'Iorio, Federica Solca, Silvia Torre, Eleonora Colombo, Alessio Maranzano, Alberto De Lorenzo, Valerio Patisso, Mauro Treddenti, Claudia Morelli, Alberto Doretti, Luca Maderna, Federico Verde, Roberta Ferrucci, Sergio Barbieri, Fabiana Ruggiero, Alberto Priori, Vincenzo Silani, Nicola Ticozzi, Gabriella Santangelo, Andrea Ciammola, Barbara Poletti
{"title":"Ecological Validity of the Montreal Cognitive Assessment in Non-Demented Parkinson's Disease Patients.","authors":"Edoardo Nicolò Aiello, Alfonsina D'Iorio, Federica Solca, Silvia Torre, Eleonora Colombo, Alessio Maranzano, Alberto De Lorenzo, Valerio Patisso, Mauro Treddenti, Claudia Morelli, Alberto Doretti, Luca Maderna, Federico Verde, Roberta Ferrucci, Sergio Barbieri, Fabiana Ruggiero, Alberto Priori, Vincenzo Silani, Nicola Ticozzi, Gabriella Santangelo, Andrea Ciammola, Barbara Poletti","doi":"10.1159/000532115","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The ecological validity of performance-based cognitive screeners needs to be tested in order for them to be fully recommended for use within clinical practice and research.</p><p><strong>Objectives: </strong>The objective of this study was to examine, within an Italian cohort of non-demented Parkinson's disease (PD) patients, the ecological validity of the Montreal Cognitive Assessment (MoCA) by assessing its association with (1) functional independence (FI), (2) quality of life (QoL), and (3) behavioural-psychological (BP) outcomes.</p><p><strong>Methods: </strong>Seventy-four non-demented PD patients were administered the MoCA and underwent motor functional - i.e., Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoehn-Yahr Scale (HY), and Schwab and England Scale (SES) -, behavioural and psychological - i.e., State- and Trait-Anxiety Inventory-Form Y (STAI-Y1/-Y2), Beck Depression Inventory (BDI), and Dimensional Apathy Scale (DAS) - and QoL evaluations - i.e., MOS 36-Item Short Form Health Survey (SF-36). Associations of interest against FI, QoL, and BP outcomes were tested via Bonferroni-corrected Pearson's/Spearman's correlations while covarying for demographics, disease duration as well as UPDRS-III, UPDRS-IV, and HY scores. Intake of psychotropic drugs was also covaried when assessing the association between the MoCA and BP/QoL measures.</p><p><strong>Results: </strong>MoCA scores were significantly associated with the SES (rs(73) = 0.34; p = 0.005) and the DAS-Executive (r(67) = -0.47; p < 0.001), while not to other FI/BP outcomes and QoL measures.</p><p><strong>Conclusions: </strong>The MoCA is a valid estimate of daily life functional autonomy in non-demented PD patients, also reflecting apathetic features of a dysexecutive nature.</p>","PeriodicalId":19115,"journal":{"name":"Neurodegenerative Diseases","volume":" ","pages":"159-163"},"PeriodicalIF":1.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000532115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Background: The ecological validity of performance-based cognitive screeners needs to be tested in order for them to be fully recommended for use within clinical practice and research.
Objectives: The objective of this study was to examine, within an Italian cohort of non-demented Parkinson's disease (PD) patients, the ecological validity of the Montreal Cognitive Assessment (MoCA) by assessing its association with (1) functional independence (FI), (2) quality of life (QoL), and (3) behavioural-psychological (BP) outcomes.
Methods: Seventy-four non-demented PD patients were administered the MoCA and underwent motor functional - i.e., Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoehn-Yahr Scale (HY), and Schwab and England Scale (SES) -, behavioural and psychological - i.e., State- and Trait-Anxiety Inventory-Form Y (STAI-Y1/-Y2), Beck Depression Inventory (BDI), and Dimensional Apathy Scale (DAS) - and QoL evaluations - i.e., MOS 36-Item Short Form Health Survey (SF-36). Associations of interest against FI, QoL, and BP outcomes were tested via Bonferroni-corrected Pearson's/Spearman's correlations while covarying for demographics, disease duration as well as UPDRS-III, UPDRS-IV, and HY scores. Intake of psychotropic drugs was also covaried when assessing the association between the MoCA and BP/QoL measures.
Results: MoCA scores were significantly associated with the SES (rs(73) = 0.34; p = 0.005) and the DAS-Executive (r(67) = -0.47; p < 0.001), while not to other FI/BP outcomes and QoL measures.
Conclusions: The MoCA is a valid estimate of daily life functional autonomy in non-demented PD patients, also reflecting apathetic features of a dysexecutive nature.
背景：基于绩效的认知筛查者的生态有效性需要进行测试，以便在临床实践和研究中充分推荐使用。目的：本研究的目的是通过评估蒙特利尔认知评估（MoCA）与（1）功能独立性（FI）、（2）生活质量（QoL）和（3）行为心理（BP）结果的关系，在意大利非痴呆帕金森病（PD）患者队列中检验其生态有效性。方法：74名非痴呆性帕金森病患者接受MoCA治疗，并接受运动功能量表（即统一帕金森病评定量表（UPDRS）、改良Hoehn-Yahr量表（HY）和Schwab and England量表（SES））、行为和心理量表（如状态和特质焦虑量表Y（STAI-Y1/-Y2）、Beck抑郁量表（BDI），以及维度障碍量表（DAS）和生活质量评估，即MOS 36项简式健康调查（SF-36）。通过Bonferroni校正的Pearson/Spearman相关性，同时对人口统计学、疾病持续时间以及UPDRS-III、UPDRS-IV和HY评分进行变异，来测试对FI、QoL和BP结果的兴趣相关性。在评估MoCA与血压/生活质量指标之间的相关性时，精神药物的摄入也被纳入。结果：MoCA评分和SES显著相关（rs（73）=0.34；p=0.005）和DAS Executive（r（67）=-0.47；p<；0.001），而与其他FI/BP结果和生活质量指标无关。结论：MoCA是对非痴呆PD患者日常生活功能自主性的有效评估，也反映了执行障碍的冷漠特征。
期刊介绍：
''Neurodegenerative Diseases'' is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer''s disease, Parkinson''s disease, amyotrophic lateral sclerosis, Huntington''s disease and related neurological and psychiatric disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
